Expertise in
15
conditions

Dr. Navneet S. Majhail

Hematology
TriStar Bone Marrow Transplant
2410 Patterson St Fl 5, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
22 Years of Experience
Expertise in
15
conditions
TriStar Bone Marrow Transplant
2410 Patterson St Fl 5, 
Nashville, TN 

Overview

Navneet Majhail is a Hematologist practicing medicine in Nashville, Tennessee. He has been practicing medicine for over 22 years.

Dr. Majhail is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 291 peer reviewed articles and participating in 9 clinical trials. Dr. Majhail is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OH

Hospital Affiliations

Tristar Centennial Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

TriStar Bone Marrow Transplant
2410 Patterson St Fl 5, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Phase: Early Phase 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological
Study Phase: Phase 2
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 30, 2025
Intervention Type: Drug
Study Drug: Zelenoleucel
Study Phase: Phase 2
INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors After Hematopoietic Cell Transplantation
INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors After Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Drug: Allogeneic NKG2D-Targeted CAR-Natural Killer T Cells
Study Phase: Phase 1
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
Enrollment Status: Terminated
Publish Date: October 17, 2019
Intervention Type: Other
The Effects of Pre-Transplant Music Therapy for Patients Undergoing Hematopoietic Stem Cell Transplant
The Effects of Pre-Transplant Music Therapy for Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: August 01, 2019
Intervention Type: Behavioral
Study Phase: Not Applicable
View 6 Less Clinical Trials

291 Total Publications

Corrigendum to 'Financial Toxicity, Psychological Well-Being, and Quality of Life in Hematopoietic Stem Cell Transplantation' [Transplantation and Cellular Therapy 31 (2025) 936.e1-936.e10].
Corrigendum to 'Financial Toxicity, Psychological Well-Being, and Quality of Life in Hematopoietic Stem Cell Transplantation' [Transplantation and Cellular Therapy 31 (2025) 936.e1-936.e10].
Journal: Transplantation and cellular therapy
Published: May 22, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Erika P. Hamilton
Hematology | Oncology
Expertise in
24
conditions
Dr. Erika P. Hamilton
Hematology | Oncology
Referral may be required

Scri Oncology Partners

335 24th Ave N, Ste 200, 
Nashville, TN 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erika Hamilton, MD, is an independent medical oncologist and hematologist at Ascension Saint Thomas in Nashville, Tennessee. Dr. Hamilton diagnoses and treats adults with cancer and focuses on managing care during and after chemotherapy, radiation therapy and surgery. Every appointment with Dr. Hamilton starts with a conversation. She takes the time to answer all your questions — big and small. Dr. Hamilton is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, and HER-2 Positive Breast Cancer. Dr. Hamilton is board certified in The American Board Of Internal Medicine - Medical Oncology. Dr. Hamilton is currently accepting new patients.

Expertise in
37
conditions
Expertise in
37
conditions
Referral may be required

Vanderbilt Hematology Clinic

1301 Medical Center Dr Ste 3903, 
Nashville, TN 
 (0.9 miles away)
615-322-5000
Languages Spoken:
English, Hindi, Spanish, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Nishitha Reddy is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Reddy is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Reddy is currently accepting new patients.

Expertise in
21
conditions
Dr. Denise A. Yardley
Hematology | Oncology
Expertise in
21
conditions
Dr. Denise A. Yardley
Hematology | Oncology
Referral may be required

Scri Oncology Partners

335 24th Ave N, Ste 200, 
Nashville, TN 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Denise Yardley is a Hematologist and an Oncologist practicing medicine in Nashville, Tennessee. Dr. Yardley is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Paget Disease of the Breast. Dr. Yardley is currently accepting new patients.

Frequently Asked Questions about Dr. Navneet S. Majhail

Is Dr. Navneet S. Majhail a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Navneet S. Majhail is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Navneet S. Majhail specialize in?

While Dr. Navneet S. Majhail is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Navneet S. Majhail participate in research or clinical trials?

Yes. Dr. Navneet S. Majhail has published 291 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Navneet S. Majhail's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Navneet S. Majhail accept my insurance?

Dr. Navneet S. Majhail accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Majhail's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile